Achilles Therapeutics plc (ACHL)

0,9401 +0,0401 (+4,46%) Al cierre: 04:00PM EDT

Achilles Therapeutics plc

245 Hammersmith Road
London W6 8PW
United Kingdom
44 20 8154 4600
https://www.achillestx.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 204

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Iraj Ali Ph.D.	CEO & Director	1,7M	N/A	1975
Dr. Karl Stuart Peggs M.D.	Founder & Chief Medical Officer	N/A	N/A	1967
Dr. Sergio A. Quezada Ph.D.	Founder & Chief Scientific Officer	N/A	N/A	1975
Mr. Robert Coutts	Chief Financial Officer	N/A	N/A	1984
Dr. Mark William Lowdell BSc, FRCPath, MICR, MSc, Ph.D.	Founder	N/A	N/A	1963
Dr. Charles Swanton FMEDSCI, M.D., Ph.D.	Founder	N/A	N/A	1973
Mr. Lee M. Stern	Vice President of Investor Relations & External Communications	N/A	N/A	N/A
Mr. Daniel Carey Cazel Hood	General Counsel & Company Secretary	N/A	N/A	N/A
Julia Wilson	Head of Communications	N/A	N/A	N/A
Mr. Tariq Ahmed	Executive Vice President of People	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Gobierno corporativo

El ISS Governance QualityScore de Achilles Therapeutics plc, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.